Polypeptides for the treatment of diseases
A polypeptide having the general amino acid sequence Z 1 IX 2 RWX 5 X 6 KX 8 PX 10 X 11 SZ 3 , wherein X 2 =V, M or L, X 5 =S or T, X 6 =K or R, X 8 =V, M, L or F, X 10 =Q or C, X 11 =V, M or F; Z 1 =0, Z 2 , or pyro glutamate, wherein Z 2 is a modification of the amino group of the N-terminal amino acid having the structure —NR 2 R 3 wherein R 2 and/or R 3 are independently from each other H or an acyl, alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; Z 3 =0, or Z 4 , wherein Z 4 is a modification of the carboxyl group of the C-terminal amino acid having the structure —C(O)—O—R 1 or —C(O)—NR 2 R 3 , wherein R 1 is an alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; and R 2 and R 3 are defined as above.
1. A polypeptide having the general amino acid sequence written in the single letter code
Z 1 IX 2 RWX 5 X 6 KX 8 PQX 11 SZ 3 ,
wherein
X 2 =V, M or L,
X 5 =S,
X 6 =K or R,
X 8 =V, M, L or F,
X 11 =V, M or F,
Z 1 =0, Z 2 , or pyro glutamate, wherein Z 2 is a modification of the N-terminal nitrogen atom of the peptide chain which modification forms together with the amino group of the N-terminal amino acid of the peptide a moiety having the structure —NR 2 R 3 wherein R 2 and/or R 3 are independently from each other H or a substituted or unsubstituted acyl, alkyl, aryl, aralkyl, cyclo alkyl or heterocyclo to alkyl group;
Z 3 =0, or Z 4 , wherein Z 4 is a modification of the C-terminal carboxyl group of the peptide chain, which modification forms together with the carboxyl group of the C-terminal amino acid of the peptide a moiety having the structure —C(O)—O—R 1 or —C(O)—NR 2 R 3 , wherein R 1 is a substituted or unsubstituted alkyl, aryl, aralkyl, cyclo alkyl or heterocyclo alkyl group; and R 2 and R 3 are defined as above.
2. The polypeptide according to claim 1 , selected from the group consisting of polypeptides having the amino acid sequence IVRWSKKVPQVS (SEQ ID No. 1), ILRWSRKMPQFS (SEQ ID NO: 9), and IVRWSKKMPQVS (SEQ ID NO: 10).
3. The polypeptide according to claim 1 , wherein at least one side chain of an amino acid of said polypeptide is phosphorylated, amidated, acetylated, glycosylated, PEGylated, HESylated or combinations thereof.
4. The polypeptide according to claim 1 , wherein the polypeptide comprises at least one D-amino acid.
5. A medicament comprising at least one polypeptide according to claim 1 and a pharmaceutically acceptable carrier.
6. The medicament according to claim 5 suitable for oral, intravenous, intramuscular, intracutaneous, subcutaneous, intrathecal administration or in form of an aerosol suitable for transpulmonary administration, encapsulated in liposomes; or for use in aqueous or liposomal packaging.